BETA CRYSTALLINE MODIFICATION OF 2,2',2''-NITRILO[TRIETHYL-TRIS-(3,3',5,5'-TETRA-TERT-BUTYL-1,1'-BIPHENYL-2,2'-DIYL) PHOSPHITE]

Abstract: This invention pertains to a beta crystalline modification of 2,2',2''-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl) phosphite], to a process for preparing said modification and the use thereof for stabilizing organic materials against oxidative, thermal or light-induced degradation.

Description: Beta Crystalline Modification of 2,2 , .2"-Nitrilortriethyl-tris-(3.3 , .5.5 , -tetra-tert-butyl- 1.1 '-biphenyl-Σ^'-diyl) phosphite! This invention pertains to a novel crystalline modification of 2,2',2"-nitrilo[triethyl-tris- (3,3',5,5'-tetra-tert-butyl-l, -biphenyl-2,2'-diyl) phosphite], to a process for preparing said modification and the use thereof for stabilizing organic materials against oxidative, thermal or light-induced degradation. 2,2',2"-Nitrilo[triethyl-tris-(3,3' t 5,5'-tetra-tert-butyl-l,l '-biphenyl-2,2'-diyl) phosphite] is a compound having the formula I This compound of formula I is useful as a processing stabilizer for organic materials as taught in US-A-4318 845 and US-A-4374219. The compound of formula I is disclosed as being a white powder melting at 121-134°C. As such, the powdery product has defects in terms of handling and apparent density, exhibiting poor flowability, meterability, sto¬ rage stability and hydrolytic stability. It has now been found that the compound of formula I can be obtained in a different crystalline modification as purified crystalline particles which exhibit acceptable proper¬ ties in respect to handling, apparent density, flowability; meterability, storage stability and hydrolytic stability. The new modification is characterized by a triclinic crystalline form, melting in the range of 200-207°C as given by the peak temperature of the endotherm recorded by differential scanning calorimetry (DSC); and by an X-ray diffraction pattern obtained using Cu-Kα which exhibits diffraction angles (2Θ) of very high intensity at 8.4 and 17; lines of high intensity at 9.9, 10.6, 11.4, 17.5, 19.1, 20.2; lines of medium intensity at 4.6, 4.9, 7.1, 12.7, 13.2, 13.6, 15.3, 15.8, 16.4, 16.7, 18.4, 19.7, 21.7, 23.4; and lines of weak intensity at 7.8, 8.8, 9.4, 12, 14.1, 14.6, 21, 22.3, 22.8, 23.9, 24.7, 25.3, 25.5, 26.4, 27, 27.7, 28.4 and a re¬ lative absolute configuration of the three stereo axes of the dibenzo[d,fj[1 ,2]dioxaphos- phepin rings of R*,R*,S*. R* and S* follow the customary convention when the absolute configuration of a mole¬ cule is unknown. The nomenclature adopted here is based on recent Chemical Abstracts Service practice as described by L. C. Cross and W. Kylne, Pure Appl. Chem.45, 11-30 (1976). The instant invention also relates to processes for the preparation of this novel beta cry¬ stalline modification of the compound of formula I. One process for the preparation of the instant beta crystalline modification comprises hea¬ ting a melt of the compound of formula I at a temperature in the range of 170 to 200°C un¬ til the novel beta crystalline modification forms or optionally seed the melt with the novel beta crystalline form in order to increase the rate and efficiency of the melt crystallization. The melt crystallization is optionally carried out under reduced pressure of from 400 mm Hg to 0.1 mm Hg. The melt crystallization can also be carried out in an extruder or knea- der as described in US-A-4683 326, the relevant parts of which are herein incorporated by reference. An alternative process for the preparation of the beta crystalline modification of the com¬ pound of formula I comprises crystallizing or recrystallizing the compound of formula I from a mixture of an aromatic hydrocarbon solvent and an alcohol of 4 to 8 carbon atoms; from a mixture of an aliphatic ketone and an alcohol of 1 to 8 carbon atoms; or from a mixture of an aromatic hydrocarbon solvent and an aliphatic ketone. Examples of aromatic hydrocarbon solvents useful in the instant process are benzene, tolu¬ ene, o-xylene, m-xylene, p-xylene, 1,2,3-trimethylbenzene, 1,3,5-trimethylbenzene, 1,2,4- trimethylbenzene, 1,2,4,5-tetramethylbenzene, ethylbenzene, cumene, o-cymene, m-cy¬ mene, p-cymene, o-diisopropylbenzene, m-diisopropylbenzene, p-diisopropylbenzene, and mixtures of such aromatic hydrocarbon solvents. Examples of alcohols useful in the instant process are methanol, ethanol, 1-propanol, iso¬ propanol, 1-butanol, 2-butanol, tert-butyl alcohol, isobutanol, amyl alcohol, 1-hexanol, 2- ethylhexanol, 1-octanol and mixtures of such alkanols. Examples of aliphatic ketones are acetone, 2-butanone, 2-pentanone, 3-pentanone, 2-hep- tanone and the like. The preferred process for preparing the novel beta crystalline modification is by crystalli¬ zing or recrystallizing the compound of formula I from a mixture of benzene, toluene, o- xylene, m-xylene, p-xylene, 1,2,3-trimethylbenzene, 1,3,5-trimethylbenzene, 1,2,4-tri- methylbenzene, 1,2,4,5-tetramethylbenzene, ethylbenzene, cumene, o-cymene, m-cymene, p-cymene, o-diisopropylbenzene, m-diisopropylbenzene or p-diisopropylbenzene and 1-butanol, 2-butanol, tert-butyl alcohol, isobutanol, amyl alcohol, 1-hexanol, 2-ethylhexa- nol or 1-octanol; from a mixture of acetone, 2-butanone, 2-pentanone, 3-pentanone or 2- heptanone and methanol, ethanol, 1-propanol, isopropanol, 1-butanol, 2-butanol, tert-butyl alcohol, isobutanol, amyl alcohol, 1-hexanol, 2-ethylhexanol or 1-octanol; or from a mix¬ ture of benzene, toluene, o-xylene, m-xylene, p-xylene, 1,2,3-trimethylbenzene, 1,3,5-tri- methylbenzene, 1,2,4-trimethylbenzene, 1,2,4,5-tetramethylbenzene, ethylbenzene, cu¬ mene, o-cymene, m-cymene, p-cymene, o-diisopropylbenzene, m-diisopropylbenzene or p-diisopropylbenzene and acetone, 2-butanone, 2-pentanone, 3-pentanone or 2 heptanone. A preferred process for preparing the novel beta crystalline modification is also by crystal¬ lizing or recrystallizing the compound of formula I from a mixture of benzene, toluene, o- xylene, m-xylene or p-xylene and 1-butanol, 2-butanol or isobutanol; from a mixture of acetone or 2-butanone and isopropanol, 1-butanol or 2-butanol; or from a mixture of ben¬ zene, toluene, o-xylene, m-xylene or p-xylene and acetone or 2-butanone. An especially preferred process for preparing the novel beta crystalline modification is by crystallizing or recrystallizing the compound of formula I from a mixture of toluene and 1-butanol; from a mixture of 2-butanone and 1-butanol; or from a mixture of toluene and acetone. The instant invention relates also to the beta, triclinic crystalline form of 2,2',2"-nitrilo[tri- ethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,l'-biphenyl-2,2'-diyl) phosphite], characterized by melting in the range of 200-207°C and by an X-ray diffraction pattern exhibiting lines of very high intensity at 8.4 and 17; lines of high intensity at 9.9, 10.6, 11.4, 17.5, 19.1, 20.2; lines of medium intensity at 4.6, 4.9, 7.1, 12.7, 13.2, 13.6, 15.3, 15.8, 16.4, 16.7, 18.4, 19.7, 21.7, 23.4; and lines of weak intensity at 7.8, 8.8, 9.4, 12, 14.1, 14.6, 21, 22.3, 22.8, 23.9, 24.7, 25.3, 25.5, 26.4, 27, 27.7, 28.4 and a relative absolute configuration of the three stereo axes of the dibenzo[d,f][l,3,2]dioxaphosphepin rings of R*,R*,S*, obtainable by heating a melt of said compound at a temperature in the range of 170 to 200°C to crystal¬ lize the novel beta crystalline modification, or by crystallizing or recrystallizing said com¬ pound from a mixture of an aromatic hydrocarbon solvent and an alcohol of 4 to 8 carbon atoms; from a mixture of an aliphatic ketone and an alcohol of 1 to 8 carbon atoms; or from a mixture of an aromatic hydrocarbon solvent and an aliphatic ketone. The beta, triclinic crystalline form of formula I according to the invention is highly sui¬ table for stabilizing organic materials against oxidative, thermal or light-induced degrada¬ tion. Examples of such organic materials are: 1. Polymers of monoolefins and diolefins, for example polypropylene, polyisobutylene, polybut-1-ene, poly-4-methylpent-l-ene, polyisoprene or polybutadiene, as well as poly¬ mers of cycloolefins, for instance of cyclopentene or norbornene, polyethylene (which optionally can be crosslinked), for example high density polyethylene (HDPE), low density polyethylene (LDPE), linear low density polyethylene (LLDPE), branched low density polyethylene (BLDPE). Polyolefins, i.e. the polymers of monoolefins exemplified in the preceding paragraph, preferably polyethylene and polypropylene, can be prepared by different, and especially by the following, methods: a) radical polymerisation (normally under high pressure and at elevated temperature). b) catalytic polymerisation using a catalyst that normally contains one or more than one metal of groups IVb, Vb, VIb or Vm of the Periodic Table. These metals usually have one or more than one ligand, typically oxides, halides, alcoholates, esters, ethers, amines, alkyls, alkenyls and/or aryls that may be either π- or σ-coordinated. These metal complexes may be in the free form or fixed on substrates, typically on activated magnesium chloride, titanium(m) chloride, alumina or silicon oxide. These catalysts may be soluble or insoluble in the polymerisation medium. The catalysts can be used by themselves in the polymerisation or further activators may be used, typically metal alkyls, metal hydrides, metal alkyl halides, metal alkyl oxides or metal alkyloxanes, said metals being elements of groups la, Ha and/or Ilia of the Periodic Table. The activators may be modified conveniently with further ester, ether, amine or silyl ether groups. These catalyst systems are usually termed Phillips, Standard Oil Indiana, Ziegler (-Natta), TNZ (DuPont), metallocene or single site catalysts (SSC). 2. Mixtures of the polymers mentioned under 1), for example mixtures of polypropylene with polyisobutylene, polypropylene with polyethylene (for example PP/HDPE, PP/LDPE) and mixtures of different types of polyethylene (for example LDPE/HDPE). 3. Copolymers of monoolefins and diolefins with each other or with other vinyl mono¬ mers, for example ethylene/propylene copolymers, linear low density polyethylene (LLDPE) and mixtures thereof with low density polyethylene (LDPE), propylene/but- 1-ene copolymers, propylene/isobutylene copolymers, ethylene/but-1-ene copolymers, ethylene hexene copolymers, ethylene/methylpentene copolymers, ethylene heptene copolymers, ethylene/octene copolymers, propylene/butadiene copolymers, isobutylene/- isoprene copolymers, ethylene/alkyl acrylate copolymers, ethylene/alkyl methacrylate copolymers, ethylene vinyl acetate copolymers and their copolymers with carbon mon¬ oxide or ethylene/acrylic acid copolymers and their salts (ionomers) as well as terpoly- mers of ethylene with propylene and a diene such as hexadiene, dicyclopentadiene or ethy- lidene-norbornene; and mixtures of such copolymers with one another and with polymers mentioned in 1) above, for example polypropylene/ethylene-propylene copolymers, LDPE ethylene-vinyl acetate copolymers (EVA), LDPE ethylene-acrylic acid copolymers (EAA), LLDPE/EVA, LLDPE/EAA and alternating or random polyalkylene/carbon mon¬ oxide copolymers and mixtures thereof with other polymers, for example polyamides. 4. Hydrocarbon resins (for example C 5 -C 9 ) including hydrogenated modifications thereof (e.g. tackifiers) and mixtures of polyalkylenes and starch. 5. Polystyrene, poly(p-methylstyrene), poly(α-methylstyrene). 6. Copolymers of styrene or α-methylstyrene with dienes or acrylic derivatives, for example styrene/butadiene, styrene/acrylonitrile, styrene/alkyl methacrylate, styrene buta- diene/alkyl acrylate, styrene butadiene/alkyl methacrylate, styrene/maleic anhydride, styrene/acrylonitrile methyl acrylate; mixtures of high impact strength of styrene copoly¬ mers and another polymer, for example a polyacrylate, a diene polymer or an ethylene/- propylene/diene terpolymer, and block copolymers of styrene such as styrene/butadiene/- styrene, styrene isoprene/styrene, styrene ethylene/butylene/styrene or styrene/ethylene - propylene/ styrene. 7. Graft copolymers of styrene or α-methylstyrene, for example styrene on polybutadiene, styrene on polybutadiene-styrene or polybutadiene-acrylonitrile copolymers; styrene and acrylonitrile (or methacrylonitrile) on polybutadiene; styrene, acrylonitrile and methyl methacrylate on polybutadiene; styrene and maleic anhydride on polybutadiene; styrene, acrylonitrile and maleic anhydride or maleimide on polybutadiene; styrene and maleimide on polybutadiene; styrene and alkyl acrylates or methacrylates on polybutadiene; styrene and acrylonitrile on ethylene/propylene/diene terpolymers; styrene and acrylonitrile on polyalkyl acrylates or polyalkyl methacrylates, styrene and acrylonitrile on acrylate buta- diene copolymers, as well as mixtures thereof with the copolymers listed under 6), for example the copolymer mixtures known as ABS, MBS, ASA or AES polymers. 8. Halogen-containing polymers such as polychloroprene, chlorinated rubbers, chlorinated or sulfochlorinated polyethylene, copolymers of ethylene and chlorinated ethylene, epi- chlorohydrin homo- and copolymers, especially polymers of halogen-containing vinyl compounds, for example polyvinyl chloride, polyvinylidene chloride, polyvinyl fluoride, polyvinylidene fluoride, as well as copolymers thereof such as vinyl chloride vinylidene chloride, vinyl chloride vinyl acetate or vinyHdene chloride/vinyl acetate copolymers. 9. Polymers derived from α,β-unsaturated acids and derivatives thereof such as polyacry- lates and polymethacrylates; polymethyl methacrylates, polyacrylamides and polyacrylo- nitriles, impact-modified with butyl acrylate. 10. Copolymers of the monomers mentioned under 9) with each other or with other unsaturated monomers, for example acrylonitrile butadiene copolymers, acrylonitrile/- alkyl acrylate copolymers, acrylonitrile/alkoxyalkyl acrylate or acrylonitrile/vinyl halide copolymers or acrylonitrile/ alkyl methacrylate/butadiene terpolymers. 11. Polymers derived from unsaturated alcohols and amines or the acyl derivatives or acetals thereof, for example polyvinyl alcohol, polyvinyl acetate, polyvinyl stearate, poly¬ vinyl benzoate, polyvinyl maleate, polyvinyl butyral, polyallyl phthalate or polyallyl melamine; as well as their copolymers with olefins mentioned in 1) above. 12. Homopolymers and copolymers of cyclic ethers such as polyalkylene glycols, poly¬ ethylene oxide, polypropylene oxide or copolymers thereof with bisglycidyl ethers. 13. Polyacetals such as polyoxymethylene and those polyoxymethylenes which contain ethylene oxide as a comonomer, polyacetals modified with thermoplastic polyurethanes, acrylates or MBS. 14. Polyphenylene oxides and sulfides, and mixtures of polyphenylene oxides with sty¬ rene polymers or polyamides. 15. Polyurethanes derived from hydroxyl-terminated polyethers, polyesters or polybuta- dienes on the one hand and aliphatic or aromatic polyisocyanates on the other, as well as precursors thereof. 16. Polyamides and copolyamides derived from diamines and dicarboxylic acids and/or from aminocarboxylic acids or the corresponding lactams, for example polyamide 4, poly¬ amide 6, polyamide 6/6, 6/10, 6/9, 6/12, 4/6, 12/12, polyamide 11, polyamide 12, aromatic polyamides starting from m-xylene diamine and adipic acid; polyamides prepared from hexamethylenediamine and isophthalic or/and terephthalic acid and with or without an elastomer as modifier, for example poly-2,4,4,-trimethylhexamethylene terephthalamide or poly-m-phenylene isophthalamide; and also block copolymers of the aforementioned polyamides with polyolefins, olefin copolymers, ionomers or chemically bonded or graf¬ ted elastomers; or with polyethers, e.g. with polyethylene glycol, polypropylene glycol or polytetramethylene glycol; as well as polyamides or copolyamides modified with EPDM or ABS; and polyamides condensed during processing (RIM polyamide systems). 17. Polyureas, polyimides, polyamide-imides and polybenzimidazoles. 18. Polyesters derived from dicarboxylic acids and diols and/or from hydroxycarboxylic acids or the corresponding lactones, for example polyethylene terephthalate, polybutylene terephthalate, poly-l,4-dimethylolcyclohexane terephthalate and polyhydroxybenzoates, as well as block copolyether esters derived from hydroxyl-terminated polyethers; and also polyesters modified with polycarbonates or MBS. 19. Polycarbonates and polyester carbonates. 20. Polysulfones, polyether sulfones and polyether ketones. 21. Crosslinked polymers derived from aldehydes on the one hand and phenols, ureas and melamines on the other hand, such as phenol/formaldehyde resins, urea/formaldehyde resins and melamine/formaldehyde resins,, 22. Drying and non-drying alkyd resins. 23. Unsaturated polyester resins derived from copolyesters of saturated and unsaturated dicarboxylic acids with polyhydric alcohols and vinyl compounds as crosslinking agents, and also halogen-containing modifications thereof of low flammability. 24. Crossϋnkable acrylic resins derived from substituted acrylates, for example epoxy acrylates, urethane acrylates or polyester acrylates. 25. Alkyd resins, polyester resins and acrylate resins crosslinked with melamine resins, urea resins, polyisocyanates or epoxy resins. 26. Crosslinked epoxy resins derived from polyepoxides, for example from bisglycidyl ethers or from cycloaliphatic diepoxides. 27. Natural polymers such as cellulose, rubber, gelatin and chemically modified homolo¬ gous derivatives thereof, for example cellulose acetates, cellulose propionates and cellu¬ lose butyrates, or the cellulose ethers such as methyl cellulose; as well as rosins and their derivatives. 28. Blends of the aforementioned polymers (polyblends), for example PP/EPDM, Poly- amide EPDM or ABS, PVC EVA, PVQABS, PVC/MBS, PC ABS, PBTP/ABS, PC/ASA, PC PBT, PVC CPE, PVC/acrylates, POM thermoplastic PUR, Pαthermoplastic PUR, POM/acrylate, POM MBS, PPO/HIPS, PPO/PA 6.6 and copolymers, PA/HDPE, PA/PP, PA/PPO. 29. Naturally occurring and synthetic organic materials which are pure monomeric com¬ pounds or mixtures of such compounds, for example mineral oils, animal and vegetable fats, oil and waxes, or oils, fats and waxes based on synthetic esters (e.g. phthalates, adi- pates, phosphates or trimellitates) and also mixtures of synthetic esters with mineral oils in any weight ratios, typically those used as spinning compositions, as well as aqueous emul¬ sions of such materials. 30. Aqueous emulsions of natural or synthetic rubber, e.g. natural latex or latices of carboxylated styrene/butadiene copolymers. Accordingly, the invention also relates to compositions comprising (a) an organic material subjected to oxidative, thermal or light-induced degradation and (b) the beta, triclinic cry¬ stalline form of 2,2',2 ,, -nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,l'-biphenyl-2,2'-di- yl) phosphite]. Preferably, the organic materials to be protected are natural, semi-synthetic or, preferably, synthetic organic materials. Particular preference is given to thermoplastic polymers, in particular PVC or polyolefins, especially polyethylene and polypropylene. The action of the compounds according to the invention against thermal and oxidative de¬ gradation, especially under thermal stress, such as occurs during processing of thermoplas¬ tics, may be mentioned in particular. Accordingly, the compounds according to the inven¬ tion are highly suitable for use as processing stabilizers. Preferably, the beta, triclinic crystalline form of 2,2\2"-mtrilo[triethyl-tris-(3,3\5,5 , -te- tra-tert-butyl-l,r-biphenyl-2,2'-diyl) phosphite] according to the invention is added to the material to be stabilized in amounts of 0.01 to 10%, for example 0.01 to 5%, preferably 0.05 to 3%, in particular 0.05 to 1%, relative to the weight of the organic material to be stabilized. The compositions according to the invention can contain, in addition to the beta, triclinic crystalline form of 2,2',2"-nitrilo[triethyl-tris-(3,3'^,5'-tetra-tert-butyl-l,l'-biphenyl- 2,2'-diyl) phosphite], further co-stabilizers, for example the following: 1. Antioxidants 1.1. Alkylated monophenols, for example 2,6-di-tert-butyl-4-methylphenol, 2-tert-butyl- 4,6-dimethylphenol, 2,6-di-tert-butyl-4-ethylphenol, 2,6-di-tert-butyl-4-n-butylphenol, 2,6-di-tert-butyl-4-isobutylphenol, 2,6-dicycIopentyl-4-methylphenol, 2-(α-methylcyclo- hexyl)-4,6-dimethylphenol, 2,6-dioctadecyl-4-methylphenol, 2,4,6-tricyclohexylphenol, 2,6-di-tert-butyl-4-methoxymethylphenol, 2,6-di-nonyl-4-methylphenol, 2,4-dimethyl-6- (1 '-methylundec- -yl)phenol, 2,4-dimethyl-6-(l'-methylheptadec- 1 '-yl)phenol, 2,4-di- methyl-6-( -methyltridec- -yl)phenol and mixtures thereof. 1.2. Alkylthiomethylphenols, for example 2,4-dioctylthiomethyl-6-tert-butylphenol, 2,4-dioctylthiomethyl-6-methylphenol, 2,4-dioctylthiomethyl-6-ethylphenol, 2,6-di-do- decylthiomethyl-4-nonylphenol. 1.3. Hvdroquinones and alkylated hydroquinones. for example 2,6-di-tert-butyl-4- methoxyphenol, 2,5-di-tert-butylhydroquinone, 2,5-di-tert-amylhydroquinone, 2,6-di- phenyl-4-octadecyloxyphenol, 2,6-di-tert-butylhydroquinone, 2,5-di-tert-butyl-4-hydroxy- anisole, 3,5-di-tert-butyl-4-hydroxyanisole, 3,5-di-tert-butyl-4-hydroxyphenyl stearate, bis-(3,5-di-tert-butyl-4-hydroxyphenyl) adipate. 1.4. Hvdroxylated thiodiphenyl ethers, for example 2,2'-thiobis(6-tert-butyl-4-methyl- phenol), 2,2'-thiobis(4-octylphenol), 4,4 , -thiobis(6-tert-butyl-3-methylphenol), 4,4'-tMo- bis(6-tert-butyl-2-methylphenol), 4,4'-thiobis-(3,6-di-sec-amylphenol), 4,4 , -bis-(2,6-dim- ethyl-4-hydroxyphenyl) disulfide. 1.5. Alkylidenebisphenols, for example 2,2'-methylenebis(6-tert-butyl-4-methylphenol), 2,2'-methylenebis(6-tert-butyl-4-ethylphenol), 2,2'-methylenebis[4-methyl-6-(α-methyl- cyclohexyl)phenol], 2,2'-methylenebis(4-methyl-6-cyclohexylphenol), 2,2'-methylene- bis(6-nonyl-4-methylphenol), 2,2'-methylenebis(4,6-di-tert-butylphenol), 2,2'-ethylidene- bis(4,6-di-tert-butylphenol), 2,2'-ethylidenebis(6-tert-butyl-4-isobutylphenol), 2,2'-methy- lenebis[6-(α-methylbenzyl)-4-nonylphenol], 2,2'-methylenebis[6-(α,α-dimethylbenzyl)- 4-nonylphenol], 4,4'-methylenebis(2,6-di-tert-butylphenol), 4,4'-methylenebis(6-tert- butyl-2-methylphenol), l,l-bis(5-tert-butyl-4-hydroxy-2-methylphenyl)butane, 2,6-bis(3- tert-butyl-5-methyl-2-hydroxybenzyl)-4-methylphenol, 1 , 1 ,3-tris(5-tert-butyl-4-hydroxy- 2-methylphenyl)butane, 1 , 1 -bis(5-tert-butyl-4-hydroxy-2-methyl-phenyl)-3-n-dodecylmer- captobutane, ethylene glycol bis[3,3-bis(3'-tert-butyl-4'-hydroxyphenyl)butyrate], bis(3- tert-butyl-4-hydroxy-5-methyl-phenyl)dicyclopentadiene, bis[2-(3'-tert-butyl-2'-hydroxy- 5'-methylbenzyl)-6-tert-butyl-4-methylphenyl]terephthalate, l,l-bis-(3,5-dimethyl-2- hydroxyphenyl)butane, 2,2-bis-(3,5-di-tert-butyl-4-hydroxyphenyl)propane, 2,2-bis-(5- tert-butyl-4-hydroxy2-methylphenyl)-4-n-dodecylmercaptobutane, l,l,5,5-tetra-(5-tert- butyl-4-hydroxy2-methylphenyl)pentane. 1.6. 0-. N- and S-benzyl compounds, for example S.S.S'.S'-tetra-tert-butyM^ -dihydroxy- dibenzyl ether, octadecyl-4-hydnoxy-3,5-dimethylbenzylmercaptoacetate, tris-(3,5-di-tert- butyl-4-hydroxybenzyl)amine, bis(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)dithio- terephthalate, bis(3,5-di-tert-butyl-4-hydroxybenzyl)sulfide, isooctyl-3,5di-tert-butyl-4- hydroxybenzylmercaptoacetate. 1.7. Hydroxybenzylated malonates. for example dioctadecyl-2,2-bis-(3,5-di-tert-butyl-2- hydroxybenzyl)-malonate, di-octadecyl-2-(3-tert-butyl-4-hydroxy-5-methylbenzyl)-malo- nate, di-dodecylmercaptoethyl-2,2-bis-(3,5-di-tert-butyl-4-hydroxybenzyl)malonate, bis- [4-(l,l,3,3-tetramethylbutyl)phenyl]-2^-bis(3,5-di-tert-butyl-4-hydroxybenzyl)malonate. 1.8. Aromatic hvdroxybenzyl compounds, for example l,3,5-tris-(3,5-di-tert-butyl-4-hy- droxybenzyl)-2,4,6-trimethylbenzene, l,4-bis(3,5-di-tert-butyl-4-hydroxybenzyl)-2,3,5,6- tetramethylbenzene, 2,4,6-tris(3,5-di-tert-butyl-4-hydroxybenzyl)phenol. 1.9. Triazine Compounds, for example 2,4-bis(octylmercapto)-6-(3,5-di-tert-butyl-4- hydroxyanilino)-l,3,5-triazine, 2-octylmercapto-4,6-bis(3,5-di-tert-butyl-4-hydroxy- anilino)-l,3,5-triazine, 2-octylmercapto-4,6-bis(3^-di-tert-butyl-4-hydroxyphenoxy)- 1,3,5-triazine, 2,4,6-tris(3,5-di-tert-butyl-4-hydroxyphenoxy)-l,2,3-triazine, 1 ,5-tris- (3,5-di-tert-butyl-4-hydroxybenzyl)isocyanurate, l,3,5-tris(4-tert-butyl-3-hydroxy-2,6-di- methylbenzyl)isocyanurate, 2,4,6-tris(3,5-di-tert-butyl-4-hydroxyphenylethyl)-l,3,5-tri- azine, l,3,5-tris(3,5-di-tert-butyl-4-hydroxyphenylpropionyl)-hexahydro-l,3,5-triazine, l,3,5-tris(3,5-dicyclohexyl-4-hydroxybenzyl)isocyanurate. 1.10. Benzylphosphonates, for example dimethyl-2,5-di-tert-butyl-4-hydroxybenzylphos- phonate, diethyl-3,5-di-tert-butyl-4-hydroxybenzylphosphonate, dioctadecyl3,5-di-tert- butyl-4-hydroxybenzylphosphonate, dioctadecyl-5-tert-butyl-4-hydroxy3-methylbenzyl- phosphonate, the calcium salt of the monoethyl ester of 3,5-di-tert-butyl-4-hydroxybenzyl- phosphonic acid. 1.11. Acylaminophenols. for example 4-hydroxylauranilide, 4-hydroxystearanilide, octyl N-(3,5-di-tert-butyl-4-hydroxyphenyl)carbamate. 1.12. Esters of β-(3,5-di-tert-butyl-4-hydroxyphenyl)propionic acid with mono- or poly¬ hydric alcohols, e.g. with methanol, ethanol, octadecanol, 1,6-hexanediol, 1,9-nonanediol, ethylene glycol, 1,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethylene glycol, triethylene glycol, pentaerythritol, tris(hydroxyethyl) isocyanurate, N,N'-bis(hy- droxyethyl)oxamide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, tri- methylolpropane, 4-hydroxymethyl-l-phospha-2,6,7-trioxabicyclo[2.2.2]octane. 1.13. Esters of β-(5-tert-butyl-4-hvdroxy-3-methylphenyl)propionic acid with mono- or polyhydric alcohols, e.g. with methanol, ethanol, octadecanol, 1,6-hexanediol, 1,9-nonane- diol, ethylene glycol, 1,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethylene glycol, triethylene glycol, pentaerythritol, tris(hydroxyethyl) isocyanurate, N,N'-bis- (hydroxyethyl)oxamide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, tri- methylolpropane, 4-hydroxymethyl-l-phospha-2,6,7-trioxabicyclo[2.2.2]octane. 1.14 Esters of β-(3,5-dicyclohexyl-4-hvdroxyphenyl)propionic acid with mono- or poly¬ hydric alcohols, e.g. with methanol, ethanol, octadecanol, 1,6-hexanediol, 1,9-nonanediol, ethylene glycol, 1,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethylene glycol, triethylene glycol, pentaerythritol, tris(hydroxyethyl) isocyanurate, N,N'-bis(hy- droxyethyl)oxamide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, tri- methylolpropane, 4-hydroxymethyl-l-phospha-2,6,7-trioxabicyclo[2.2.2]octane. 1.15 Esters of 3.5-di-tert-butyl-4-hydroxyphenyl acetic acid with mono- or polyhydric alcohols, e.g. with methanol, ethanol, octadecanol, 1,6-hexanediol, 1,9-nonanediol, ethy¬ lene glycol, 1,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethylene glycol, triethylene glycol, pentaerythritol, tris(hydroxyethyl) isocyanurate, N,N'-bis(hydroxy- ethyl)oxamide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, trimethylolpro- pane, 4-hydroxymethyl-l-phospha-2,6,7-trioxabicyclo[2.2.2]octane. 1.16. Amides of β-(3.5-di-tett-butyl-4-hvdroxyphenyl)propionic acid e.g. N,N'-bis(3,5-di- tert-butyl-4-hydroxyphenylpropionyl)hexamethylenediamine, N,N'-bis(3,5-di-tert-butyl- 4-hydroxyphenylpropionyl)trimethylenediamine, N,N'-bis(3,5-di-tert-butyl-4-hydroxy- phenylpropionyl)hydrazine. 2. UV absorbers and light stabilisers 2.1. 2-(2'-Hydroxyphenyl)benzotriazoles, for example 2-(2'-hydroxy-5'-methylphenyl)- benzotriazole, 2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)benzotriazole, 2-(5'-tert-butyl-2'- hydroxyphenyl)benzotriazole, 2-(2'-hydroxy-5'-(l,l,3,3-tetramethylbutyl)phenyl)benzo- triazole, 2-(3 , ,5'-di-tert-butyl-2'-hydrOxyphenyl)-5-chloro-benzotriazole, 2-(3'-tert-butyl- 2'-hydroxy-5'-methylphenyl)-5-chloro-benzotriazole, 2-(3'-sec-butyl-5'-tert-butyl-2'- hydroxyphenyl)benzotriazole, 2-(2'-hydroxy-4'-octyloxyphenyl)benzotriazole, 2-(3',5'- di-tert-amyl-2'-hydroxyphenyl)benzotriazole, 2-(3\5'-bis-(α,α-dimethylbenzyl)-2'- hydroxyphenyl)benzotriazole, mixture of 2-(3'-tert-butyl-2'-hydroxy-5'-(2-octyloxycar- bonylethyl)phenyl)-5-chloro-benzotriazole, 2-(3'-tert-butyl-5'-[2-(2-ethylhexyloxy car- bonylethyl]-2'-hydroxyphenyl)-5-chloro-benzotriazole, 2-(3-tert-butyl-2'-hydroxy-5 , -(2- methoxycarbonylethyl)phenyl)-5-chloro-benzotriazole, 2-(3'-tert-butyl-2'-hydroxy-5*-(2- methoxycarbonylethyl)phenyl)benzotriazole, 2-(3'-tert-butyl-2'-hydroxy-5'-(2-octyl- oxycarbonylethyl)phenyl)benzotriazole, 2-(3'-tert-butyl-5 , -[2-(2-ethylhexyloxy)carbonyl- ethyl]-2'-hydroxyphenyl)benzotriazole, 2-(3-dodecyl-2'-hydroxy-5 , -methylphenyl)benzo- triazole, and 2-(3 , -tert-butyl-2 , -hydroxy-5 , -(2-isooctyloxycarbonylethyl)phenylbenzotri- azole, 2,2'-methylene-bis[4-(l,l,3,3-tetramethylbutyl)-6-benzotriazole-2-ylphenol]; the transesterification product of 2-[3 -tert-butyl-5'-(2-methoxycarbonylethyl)-2 -hydroxy- ρhenyl]-2H-benzotriazole with polyethylene glycol 300; [R-CH 2 CH 2 -COO(CH 2 )^ j - , where R = 3 , -tert-butyl-4'-hydroxy-5 , -2H-benzotriazol-2-ylphenyl. 2.2. 2-Hydroxybenzophenones, for example the 4-hydroxy, 4-methoxy, 4-octyloxy, 4-de- cyloxy, 4-dodecyloxy, 4-benzyloxy, 4,2',4'-trihydroxy and 2'-hydroxy-4,4'-dimethoxy derivatives. 2.3. Esters of substituted and unsubstituted benzoic acids, as for example 4-tertbutyl- phenyl salicylate, phenyl salicylate, octylphenyl salicylate, dibenzoyl resorcinol, bis(4- tert-butylbenzoyl) resorcinol, benzoyl resorcinol, 2,4-di-tertbutylphenyl 3,5-di-tert-butyl- 4-hydroxybenzoate, hexadecyl 3,5-di-tert-butyl-4-hydroxybenzoate, octadecyl 3,5-di-tert- butyl-4-hydroxybenzoate, 2-methyl-4,6-di-tert-butylphenyl 3,5-di-tert-butyl-4-hydroxy- benzoate. 2.4. Acrylates, for example ethyl α-cyano-β,β-diphenylacrylate, isooctyl α-cyano-β,β-di- phenylacrylate, methyl α-carbomethoxycinnamate, methyl α-cyano-β-methyl-p-methoxy- cinnamate, butyl α-cyano-β-methyl-p-methoxy-cinnamate, methyl α-carbomethoxy-p- methoxycinnamate and N-(β-carbomethoxy-β-cyanovinyl)-2-methylindoline. 2.5. Nickel compounds, for example nickel complexes of 2,2'-thio-bis-[4-(l,l,3,3-tetra- methylbutyl)phenol], such as the 1:1 or 1:2 complex, with or without additional ligands such as n-butylamine, triethanolamine or N-cyclohexyldiethanolamine, nickel dibutyldi- thiocarbamate, nickel salts of the monoalkyl esters, e.g. the methyl or ethyl ester, of 4- hydroxy-3,5-di-tert-butylbenzylphosphonic acid, nickel complexes of ketoximes, e.g. of 2-hydroxy-4-methylphenyl undecylketoxime, nickel complexes of l-phenyl-4-lauroyl-5- hydroxypyrazole, with or without additional ligands. 2.6. Sterically hindered amines, for example bis(2,2,6,6-tetramethyl-piperidyl)sebacate, bis(2,2,6,6-tetramethyl-piperidyl)succinate, bis(l,2,2,6,6-pentamethylpiperidyl)sebacate, bis(l,2,2,6,6-pentamemylpiperidyl) n-butyl-3,5-di-.tert-butyl-4-hydroxybenzylmalonate, the condensate of l-(2-hydroxyethyl)-2,2,6,6-tetramethyl-4-hydroxypiperidine and succi- nic acid, the condensate of N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)hexamethylenedi- amine and 4-tert-octylamino-2,6-dichloro-l,3,5-triazine, tris(2,2,6,6-tetramethyl-4-piperi- dyl) nitrilotriacetate, tetrakis(2,2,6,6-tetramethyl-4- piperidyl)-l,2,3,4-butane-tetracar- boxylate, l,l'-(l,2-ethanediyl)bis(3,3,5,5-tetramethylpiperazinone), 4-benzoyl-2,2,6,6- tetramethylpiperidine, 4-stearyloxy-2,2,6,6-tetramethylpiρeridine, bis( 1,2,2,6,6-penta- methylpiperidyl)-2-n-butyl-2-(2-hydroxy-3,5-di-tert-butylbenzyl)malonate, 3-n-octyl- 7,7,9,9-tetramethyl-l,3,8-triazasprio[4.5]decan-2,4-dion, bis(l-octyloxy-2,2,6,6-tetra- methylpiperidyl)sebacate, bis(l-octyloxy-2,2,6,6-tetramethylpiperidyl)succinate, the condensate of N,N-bis-(2,2,6,6-tetramethyl-4-piperidyl)hexamethylenediamine and 4-morpholino-2,6-dichloro-l,3,5-triazine, the condensate of 2-chloro-4,6-bis(4-n-butyl- amino-2,2,6,6-tetramethylpiperidyl )-l,3,5-triazine and l,2-bis(3-aminopropylamino)- ethane, the condensate of 2-chloro-4,6-di-(4-n-butylamino-l,2,2,6,6-pentamethylpiperi- dyl)-l,3,5-triazine and l,2-bis-(3-aminopropylamino)ethane, 8-acetyl-3-dodecyl-7,7,9,9- tetramethyl-l,3,8-triazaspiro[4.5]decane-2,4-dione, 3-dodecyl-l-(2,2,6,6-tetramethyl-4- piperidyl)pyrrolidin-2,5-dione, 3-dodecyl-l-(l,2,2,6,6-pentamethyl-4-piperidyl)pyrτoli- dine-2,5-dione. 2.7. Oxamides, for example 4,4'-dioctyloxyoxaniϋde, 2,2'-dioctyloxy-5,5'-di-tert-butox- anilide, 2,2'-didodecyloxy-5,5'-di-tert-butoxanilide, 2-ethoxy-2'-ethoxanilide, N,N'- bis(3-dimethylaminopropyl)oxamide, 2-ethoxy-5-tert-butyl-2'-ethoxanilide and its mix- tore with 2-ethoxy-2'-ethyl-5,4'-di-tert-butoxanilide and mixtures of ortho- and para- methoxy-disubstituted oxanilides and mixtures of o- and p-ethoxy-disubstituted oxani- lides. 2.8. 2-(2-Hvdroχyphenyl)- 1.3.5-triazines. for example 2,4,6-tris(2-hydroxy-4-octyloxy- phenyl)- 1 ,3,5-triazine, 2-(2-hydroxy-4-octyloxyphenyl)-4,6-bis(2,4-dimethylphenyl)- 1,3,5-triazine, 2-(2,4-dihydroxyphenyl)-4,6-bis(2,4-dimethylphenyl)-l,3,5-triazine, 2,4-bis(2-hydroxy-4-propyloxyphenyl)-6-(2,4-dimethylphenyl)- 1 ,3,5-triazine, 2-(2-hy- droxy-4-octyloxyphenyl)-4,6-bis(4-methylphenyl)-l,3,5-triazine, 2-(2-hydroxy-4-dodecyl- oxyphenyl)-4,6-bis(2,4-dimethylphenyl)-l,3,5-triazine, 2-[2-hydroxy-4-(2hydroxy- 3-butyloxy-propoxy)phenyl]-4,6-bis(2,4-dimethyl)-l,3,5-triazine, 2-[2-hydroxy-4-(2- hydroxy-3-octyloxy-propyloxy)phenyl]-4,6-bis(2,4-dimethyl)- 1 ,3,5-triazine. 3. Metal deactivators, for example N,N'-diphenyloxamide, N-salicylal-N'-salicyloyl hydrazine, N,N'-bis(salicyloyl) hydrazine, N,N'-bis(3,5-di-tert-butyl-4-hydroxyphenyl- propionyl) hydrazine , 3-salicyloylamino-l,2,4-triazole, bis(benzylidene)oxalyl di- hydrazide, oxanilide, isophthaloyl dihydrazide, sebacoyl bisphenylhydrazide, N,N-di- acetyladipoyl dihydrazide, N,N-bis(salicyloyl)oxalyl dihydrazide, N,N'-bis(salicyloyl)- thiopropionyl dihydrazide. 4. Phosphites and phosphonites. for example triphenyl phosphite, diphenyl alkyl phos¬ phites, phenyl dialkyl phosphites, tris(nonylphenyl) phosphite, trilauryl phosphite, triocta- decyl phosphite, distearyl pentaerythritol diphosphite, tris(2,4-di-tert-butylphenyl) phos¬ phite, dϋsodecyl pentaerythritol diphosphite, bis(2,4-di-tert-butylphenyl) pentaerythritol diphosphite, bis(2,6-di-tert-butyl-4-methylphenyl)-pentaeryt hritol diphosphite, diisode- cyloxypentaerythritol diphosphite, bis(2,4-di-tert-butyl-6-methylphenyl)pentaerythritol di¬ phosphite, bis(2,4,6-tris(tert-butylphenyl)pentaerythritol diphsophite, tristearyl sorbitol tri- phosphite, tetrakis(2,4-di-tert-butylphenyl) 4,4'-biphenylene diphosphonite, 6-isooctyl- oxy-2,4,8,10-tetra-tert-butyl-12H-dibenz[d,g]-l,3,2-dioxaphosphocin, 6-fluoro-2,4,8,10- tetra-tert-butyl-12-methyl-dibenz[d,g]-l,3,2-dioxaphosphocin, bis(2,4-di-tert-butyl-6- methylphenyl)methylphosphite, bis(2,4-di-tert-butyl-6-methylphenyl)ethylphosphite. 5. Peroxide scavengers, for example esters of β-thiodipropionic acid, for example the lauryl, stearyl, myristyl or tridecyl esters, mercaptobenzimidazole or the zinc salt of 2-mercaptobenzimidazole, zinc dibutyldithiocarbamate, dioctadecyl disulfide, penta¬ erythritol tetrakis(β-dodecylmercapto)propionate. 6. Polyamide stabilisers, for example, copper salts in combination with iodides and/or phosphorus compounds and salts of divalent manganese. 7. Basic co-stabilisers, for example, melamine, polyvinylpyrrolidone, dicyandiamide, tri- allyl cyanurate, urea derivatives, hydrazine derivatives, amines, polyamides, polyure¬ thanes, alkali metal salts and alkaline earth metal salts of higher fatty acids for example calcium stearate, zinc stearate, magnesium behenate, magnesium stearate, sodium rici- noleate and potassium palmitate, antimony pyrocatecholate or tin pyrocatecholate. 8. Nucleating agents, for example, 4-tert-butylbenzoic acid, adipic acid, diphenylacetic acid. 9. Fillers and reinforcing agents, for example, calcium carbonate, silicates, glass fibres, asbestos, talc, kaolin, mica, barium sulfate, metal oxides and hydroxides, carbon black, graphite. 10. Other additives, for example, plasticisers, lubricants, emulsifiers, pigments, optical brighteners, flameproofing agents, antistatic agents and blowing agents. 11. Benzofuranones and indolinones. for example those disclosed in US-A-4325 863, US-A-4338 244 or US-A-5 175312, or 3-[4-(2-acetoxyethoxy)phenyl]-5,7-di-tert-butyl- benzofuran-2-one, 5,7-di-tert-butyl-3-[4-(2-stearoyloxyethoxy)phenyl]benzofuran-2-one, 3,3'-bis[5,7-di-tert-butyl-3-(4-[2-hydroxyethoxy]phenyl)benzofuran-2-one], 5,7-di-tert-bu- tyl-3-(4-ethoxyphenyl)benzofuran-2-one, 3-(4-acetoxy-3,5-dimethylphenyl)-5,7-di-tert- butyl-benzofuran-2-one, 3-(3,5-dimethyl-4-pivaloyloxyphenyl)-5,7-di-tert-butyl-benzofu- ran-2-one. The co-stabilizers, with the exception of the benzofuranones listed under 11, are added for example in concentrations of 0.01 to 10%, relative to the total weight of the material to be stabilized. Further preferred compositions comprise, in addition to components (a) and (b) further additives, in particular phenolic antioxidants, light stabilizers or processing stabilizers. Particularly preferred additives are phenolic antioxidants (item 1 of the list), sterically hin- dered amines (item 2.6 of the list), phosphites and phosphonites (item 4 of the list) and peroxide-destroying compounds (item 5.) of the list Additional additives (stabilizers) which are also particularly preferred are benzofuran-2- ones, such as described, for example, in US-A-4325 863, US-A-4338 244 or US-A-5 175312. Examples of such benzofuran-2-ones are compounds of the formula in which R π is phenyl or phenyl which is substituted by 1 to 3 alkyl radicals together having at most 18 carbon atoms, alkoxy having 1 to 12 carbon atoms, alkoxycarbonyl having 2 to 18 carbon atoms or chlorine; R 12 is hydrogen; R 14 is hydrogen, alkyl having 1 to 12 carbon atoms, cyclopentyl, cyclohexyl or chlorine; R 13 has the meaning of R 12 or R 14 or is a radical of the formula , O O O O II II II II — (CH2) n -C-NR 18 -A-NR 18 -C-(CH 2 ) n -E » — (CH 2 ) n -C-NR 18 -A-O-C-(CH 2 ) n -E . OR 16 or -D-E, in which R 16 is hydrogen, alkyl having 1 to 18 carbon atoms, alkyl having 2 to 18 carbon atoms which is interrupted by oxygen or sulfur, dialkylaminoalkyl having a total of 3 to 16 carbon atoms, cyclopentyl, cyclohexyl, phenyl or phenyl which is substituted by 1 to 3 alkyl radicals together having at most 18 carbon atoms; n is 0, 1 or 2; the substituents R 17 , independently of one another, are hydrogen, alkyl having 1 to 18 carbon atoms, cyclopentyl, cyclohexyl, phenyl, phenyl which is substituted by 1 or 2 alkyl radicals together having at most 16 carbon atoms, a radical of the formula -C 2 H 4 OH, O II -C 2 H 4 -O-C m H 2 m + ι or -G^-O-C-R^ or together with the nitrogen atom to which they are attached form a piperidine or morpholine radical; m is 1 to 18; R 2 o is hydrogen, alkyl having 1 to 22 carbon atoms or cycloalkyl having 5 to 12 carbon atoms; A is alkylene having 2 to 22 carbon atoms which may be interrupted by nitrogen, oxygen or sulfur; R 18 is hydrogen, alkyl having 1 to 18 carbon atoms, cyclopentyl, cyclohexyl, phenyl, phenyl which is substituted by 1 or 2 alkyl radicals together having at most 16 carbon atoms, or is benzyl; R 19 is alkyl having 1 to 18 carbon atoms; D is -O-, -S-, -SO-, -SO 2 - or -C(R 21 ) 2 - ; the substituents R 21 , independently of one another, are hydrogen, C r C 16 alkyl, the two R 21 together containing 1 to 16 carbon atoms, R 21 is furthermore phenyl or a radical of the formula , in which n, R 16 and R 17 are as defined above; E is a radical of the formula in which R π , R 12 and R 14 are as defined above; and R 15 is hydrogen, alkyl having 1 to 20 carbon atoms, cyclopentyl, cyclohexyl, chlorine or a O o radical of the formula -CH 2 -C-OR 16 or -CH 2 -C-N(R 17 ) 2 , in which R 16 and R 17 are as defined above, or R 15 together with R 14 forms a tetramethylene radical. Preference is given to those benzofuran-2-ones in which R 13 is hydrogen, alkyl having 1 to 12 carbon atoms, cyclopentyl, cyclohexyl, chlorine or a radical of the formula — (CH 2 j -C--OR 1 . 6 . ,— — (CH 2 Λ) — C-N(R 17 ) 2 or -D-E, in which n, R 16 , R 17 , D and E are as defined above, R 16 is in particular hydrogen, alkyl having 1 to 18 carbon atoms, cyclopentyl or cyclohexyl. Preference is given furthermore to those benzofuran-2-ones in which R π is phenyl or phenyl which is substituted by 1 or 2 alkyl radicals together having at most 12 carbon atoms; R 12 is hydrogen; R 14 is hydrogen or alkyl having 1 to 12 carbon atoms; R 13 is hydrogen, alkyl having 1 to 12 carbon atoms, , or -D-E; R 15 is hydrogen, alkyl having 1 to 20 carbon atoms, , or R 15 together with R 14 forms a tetramethylene radical, n, R 16 , R 17 , D and E being as defined at the beginning. Of particular interest are also those benzofuran-2-ones in which R π is phenyl; R 13 is hydrogen, alkyl having 1 to 12 carbon atoms or -D-E; R 1 and R 14 , independently of one another, are hydrogen or alkyl having 1 to 4 carbon atoms; and R 15 is alkyl having 1 to 20 carbon atoms, D and E being as defined at the beginning. Of special interest are finally also those benzofuran-2-ones in which R n is phenyl; R 13 is alkyl having 1 to 4 carbon atoms or -D-E; R 12 and R 14 are hydrogen; and R 15 is alkyl having 1 to 4 carbon atoms, cyclopentyl or cyclohexyl, D being a group -C(R 21 ) 2 - and E being a radical of the formula the substituents R 2 ι being identical to or different from one another and each being alkyl having 1 to 4 carbon atoms, and R π , R 12 , Rχ and R 15 being as defined. The amount of additional additives, in particular stabilizers, for example of the benzofu- ran-2-ones mentioned, can vary within wide limits. For example, 0.0005 to 10, preferably 0.001 to 5, in particular 0.01 to 2, % by weight thereof can be present in the compositions according to the invention. Incorporation of the beta, triclinic crystalline form of 2,2 , ,2"-nitrilo[triethyl-tris-(3,3',5,5'- tetra-tert-butyl-l, -biphenyl-2,2'-diyl) phosphite] and, if desired, further additives in the polymer organic material is carried out by known methods, for example before or during moulding or by applying the dissolved or dispersed compounds to the polymer organic material, if appropriate with subsequent slow evaporation of the solvent. The beta, triclinic crystalline form according to the invention can also be added to the materials to be stabi¬ lized in the form of a masterbatch containing them, for example, in a concentration of 2.5 to 25% by weight. The beta, triclinic crystalline modification according to the invention can also be added before or during polymerization or before crosslinking. The beta, triclinic crystalline modification according to the invention can be incorporated in the material to be stabilized in pure form or encapsulated in waxes, oils or polymers. The beta, triclinic crystalline modification according to the invention can also be sprayed onto the polymer to be stabilized. They are capable of diluting other additives (for example the abovementioned customary additives) or their melts, thus enabling them to be sprayed onto the polymer to be stabilized also together with these additives. Addition by spraying during deactivation of the polymerization catalysts is particularly advantageous, it being possible, for example, for the steam used for deactivation to be used for spraying. In the case of bead polymerized polyolefins, it may be advantageous, for example, to apply the beta, triclinic crystalline modification according to the invention, if desired to¬ gether with other additives, by spraying. The materials thus stabilized can be used in a wide range of forms, for example as films, fibres, tapes, moulding compositions, profiles or as binders for paints, adhesives or ce¬ ments. As already mentioned, the organic materials to be protected are preferably organic, in par¬ ticular synthetic, polymers. Of these, the materials being protected are particularly advan¬ tageously thermoplastic materials, in particular polyolefins. The excellent efficiency of the beta, triclinic crystalline form of 2,2',2"-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl- l,l'-biphenyl-2,2'-diyl) phosphite] as processing stabilizer (thermal stabilizer) should be mentioned in particular. To this end, it is advantageously added to the polymer before or during its processing. It is however also possible to stabilize other polymers (for example elastomers) or lubricants or hydraulic fluids against degradation, for example light-in¬ duced or thermal-oxidative degradation. For elastomers, see the above list of possible or¬ ganic materials. Suitable lubricants and hydraulic fluids are based, for example, on mineral or synthetic oils or mixtures thereof. Lubricants are known to one skilled in the art and described in the relevant technical literature, for example in Dieter Klamann, "Schmierstoffe und ver- wandte Produkte" (Verlag Chemie, Weinheim 1982), in Schewe-Kobek, "Das Schmier- mittel-Taschenbuch" (Dr. Alfred Huthig- Verlag, Heidelberg, 1974) and in "Ullmanns Enzyklopadie der technischen Chemie" vol. 13, pages 85-94 (Verlag Chemie, Weinheim, 1977). Accordingly, a preferred embodiment of the present invention is the use of the beta, tricli¬ nic crystalline form of 2,2',2"-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,l'-biphenyl- 2,2'-diyl) phosphite] for stabilizing organic materials against oxidative, thermal or light- induced degradation. The beta, triclinic crystalline modification according to the invention is preferably used as processing stabilizer (thermal stabilizer) of thermoplastic polymers. The present invention also provides a process for stabilizing an organic material against oxidative, thermal or light-induced degradation, which comprises incorporating therein or applying thereto the beta, triclinic crystalline form of 2,2\2"-nitrilo[triethyl-tris-(3,3',5,5'- tetra-tert-butyl-l, -biphenyl-2,2'-diyl) phosphite]. Differential scanning calorimetry (DSC) measurements are obtained on a TA Instrument Inc., 910 differential scanning calorimeter, with a 100 ml/min nitrogen purge, aligned alu¬ minum pan, temperature scan at 5°C/min to 230°C. X-ray diffraction patterns are recorded on a Philips Norelco X-ray Diffractometer unit, using Cu-Kα radiation with a nickel filter. The examples which follow further illustrate the invention. The parts or percentages given are by weight Example 1: Synthesis of the ethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,r-biphenyl-2,2'-diyl) phosphite]. The compound of formula 1, 2,2',2"-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,l'-bi- phenyl-2,2'-diyl) phosphite], is prepared according to procedure of Example 4 of US-A-4318 845. The product obtained is heated at 180°-185°C in vacuo (0.1 mm Hg) to obtain a melt The melt is heated until a crystalline mass forms, approximately 16 hours. The crystalline mass is then ground into a white powder using a mortar and pestle. A 93% yield of the novel beta crystal modification of the compound of formula I is obtained: m.p.= 206°C (the melting point is determined by differential scanning calorimetry and the peak temperature in the endotherm is recorded as the melting point). An X-ray diffraction pattern obtained using Cu-Kα exhibits diffraction angles (2Θ) of very high intensity at 8.4 and 17; lines of high intensity at 9.9, 10.6, 11.4, 17.5, 19.1, 20.2; lines of medium intensity at 4.6, 4.9, 7.1, 12.7, 13.2, 13.6, 15.3, 15.8, 16.4, 16.7, 18.4, 19.7, 21.7, 23.4; and lines of weak intensity at 7.8, 8.8, 9.4, 12, 14.1, 14.6, 21, 22.3, 22.8, 23.9, 24.7, 25.3, 25.5, 26.4, 27, 27.7, 28.4. Analysis: Calcd for C 9 oH 132 NO 9 P 3 : C 73.8; H 9.1; N 0.96 %. Found: C 73.5; H 9.4; N 0.9 %. Example 2: Synthesis of the beta, triclinic crystalline modification of 2,2',2"-nitrilo[tri- ethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,r-biphenyl-2,2'-diyl) phosphite]. The compound of formula 1, 2,2',2"-nitrilo[triethyl-tris-(3,3 , ,5,5'-tetra-tert-butyl-l,l , -bi- phenyl-2,2'-diyl) phosphite], is prepared according to procedure of Example 4 of US-A-4318 845. The product obtained is recrystallized from the following solvent systems to obtain the novel beta, triclinic crystalline modification of the instant invention. The results are summarized in Table 1. a) Melting point is determined by differential scanning calorimetry and the peak tempe¬ rature in the endotherm is recorded as the melting point Suitable crystals for X-ray analysis are grown from acetone/toluene (3.6/1, wt/wt). Intensi¬ ty data are measured on a NONIUS CAD4 automatic diffractometer as described in Table 2. The structure is solved by direct methods using SHELXS. Full-matrix least- squares refinements are carried out to a final R value of 0.083. The relative configuration is determined to be R*,R*,S*. Table 2 Crystal and Data Collection Parameters Formula 90H1 3 2NO9P3 Formula weight (g.mol" 1 ) 1464.96 Color; Habit Colorless Prism Crystal System Triclinic Space group PI Z 2 Cell parameters a = 12.493 (1) A b = 19.701 (2) A c = 21.027 (3) A α = 116.23 (l) deg β = 100.15 (l) deg γ = 91.07 (l) deg Volume v = 4542 A 3 dcalc 1.072 g/cm 3 Absorption Coefficient 0.926 mm "1 Crystal Size 0.5 x 0.3 x 0.2 mm Temperature 21° C Diffractometer Type NONIUS CAD4 Radiation CuKα (λ = 1.5418 A) Monochromator Orientated graphite crystal 20 Range 3 to 50 deg Reflections Collected 14042 R 0.083 R w 0.090 Example 3: Resistance to Hydrolysis. This example illustrates the much greater resistance to hydrolysis of the beta crystalline modification of the compound of formula I as prepared in Example 1 as compared to the lesser resistance of the compound of Example 4 of US-A-4318 845. The test compounds are exposed to 80 % relative humidity at 50°C and their rate of hydro¬ lysis is monitored by liquid chromatography. The results below are stated in the percent product remaining after 1000 hours of exposure under the conditions stated above. The re¬ sults are summarized in Table 3. Table 3: Example 4: Bulk Density This example illustrates the superior packaging properties of the novel beta crystalline modification of the compound of formula I, Example 1, over that of the powder form of Example 4 in US-A-4318 845. The apparent bulk density of the solids is measured according to the method of ASTM D-1895 (79). A higher apparent bulk density allows for a greater mass per unit volume which affords advantages in packaging of the solid product, such as lower costs for the packaging material, less storage space is required, etc. The results are listed in Table 4. Table 4: Example 5: Process Stabilization of Polypropylene at 274°C. The base formulation comprises unstabilized, high yield/high selectivity catalyzed poly¬ propylene (PROFAX® 6501, Batch No. BD07155, produced by Himont) containing 0.075% by weight of calcium stearate. The test additives are incorporated into the poly¬ propylene by dry blending or, when the additive is a liquid, using a minimum amount of methylene chloride solvent The solvent is then removed by evaporation under reduced pressure. The stabilized resin formulation is extruded at 90 rpm from a 2.54 cm diameter extruder at 274°C with a residence time of 90 seconds. After each of the first, third and fifth extrusions, the melt flow rate (in grams/10 minutes) is determined by ASTM method D1238 on the pellets obtained from the extruder. The melt flow rate is a measure of the molecular weight of the polymer and indicates whether thermal degradation is occurring during melt processing by extrusion. A minimum change in melt flow rate is favored and indicates good melt processing stabilization. A substantial increase in the melt flow de¬ notes pronounced chain degradation, i.e. poor stabilization/The results are given in Table 5 below. Table 5: AO A is neopentanetetrayl tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate). Example 6: Comparison of the X-ray diffraction data of the beta, triclinic crystalline form of formula I according to the invention (compound A) and the compound of formula I as prepared according to the procedure of Example 4 of US-A-4318 845 (compound B). The beta, triclinic crystalline form of 2,2',2"-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl- l,l'-biphenyl-2,2'-diyl) phosphite] was pepared in accordance with instant Example 2 (compound A). The state of the art modification of formula I was prepared according to the procedure of Example 4 of US-A-4318 845 and recrystallized from a mixture of ace- tonitrile and toluene (compound B). The results are summarized in Table 6. Table 6: The procedure for the X-ray analysis performed is the same as provided in instant Exam¬ ple 2. Comparison of the data readily shows a difference in structure between the instant beta, crystalline form (compound A) and the state of the art compound (compound B). The unit cell of compound B contains an entrapped molecule of toluene. This was not re¬ cognized by the authors of US-A-4318 845 or they failed to mention it In constrast the crystal cell of compound A of the instant invention does not contain a molecule of solvent from any of the claimed recrystallization solvent systems. The above fact is clearly reflected in the large difference in melting points between the beta crystalline form (compound A) and the prior art material (compound B). Additional¬ ly, this fact is seen in comparing the difference between the cell dimensions, volume and density. In particular, a significant difference can be seen by comparing the volumes of the beta crystalline form (4542 A 3 ) and the prior art material (9966 A 3 ).

Claims: WHAT IS CLAIMED IS: 1. The beta, triclinic crystalline form of 2,2 , ,2"-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert- butyl-l, -biphenyl-2,2'-diyl) phosphite], characterized by melting in the range of 200-207°C and by an X-ray diffraction pattern exhibiting lines of very high intensity at 8.4 and 17; lines of high intensity at 9.9, 10.6, 11.4, 17.5, 19.1, 20.2; lines of medium intensity at 4.6, 4.9, 7.1, 12.7, 13.2, 13.6, 15.3, 15.8, 16.4, 16.7, 18.4, 19.7, 21.7, 23.4; and lines of weak intensity at 7.8, 8.8, 9.4, 12, 14.1, 14.6, 21, 22.3, 22.8, 23.9, 24.7, 25.3, 25.5, 26.4, 27, 27.7, 28.4 and a relative absolute configuration of the three stereo axes of the diben- zo[d,f][l,3,2]dioxaphosphepin rings of R*,R*,S*. 2. A process for the preparation of the beta, triclinic crystalline form of the compound 2,2 2"-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,r-biphenyl-2,2'-diyl) phosphite] which comprises heating a melt of said compound at a temperature in the range of 170 to 200°C to crystallize the novel beta crystalline modification. 3. A process according to claim 2 which comprises seeding the melt with the novel beta crystalline form in order to increase the rate and efficiency of the melt crystallization. 4. A process according to claim 2 wherein the melt is heated under reduced pressure of from 400 mm Hg to 0.1 mm Hg. 5. A process according to claim 2 wherein the melt crystallization is carried out in an ex¬ truder or kneader. 6. A process for the preparation of the beta, triclinic crystalline form of the compound 2,2 , ,2"-nitrilo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,l'-biphenyl-2,2 , -diyl) phosphite] which comprises crystallizing or recrystallizing said compound from a mixture of an aro¬ matic hydrocarbon solvent and an alcohol of 4 to 8 carbon atoms; from a mixture of an ali¬ phatic ketone and an alcohol of 1 to 8 carbon atoms; or from a mixture of an aromatic hydrocarbon solvent and an aliphatic ketone. 7. A process according to claim 6 wherein the crystallizing or recrystallizing is from a mixture of benzene, toluene, o-xylene, m-xylene, p-xylene, 1,2,3-trimethylbenzene, 1,3,5- trimethylbenzene, 1,2,4-trimethylbenzene, 1,2,4,5-tetramethylbenzene, ethylbenzene, cu- mene, o-cymene, m-cymene, p-cymene, o-diisopropylbenzene, m-diisopropylbenzene or p-diisopropylbenzene and 1-butanol, 2-butanol, tert-butyl alcohol, isobutanol, amyl alco¬ hol, 1-hexanol, 2-ethylhexanol or 1-octanol; from a mixture of acetone, 2-butanone, 2-pen- tanone, 3-pentanone or 2-heptanone and methanol, ethanol, 1-propanol, isopropanol, 1-bu- tanol, 2-butanol, tert-butyl alcohol, isobutanol, amyl alcohol, 1-hexanol, 2-ethylhexanol or 1-octanol; or from a mixture of benzene, toluene, o-xylene, m-xylene, p-xylene, 1,2,3-tri- methylbenzene, 1,3,5-trimethylbenzene, 1,2,4-trimethylbenzene, 1,2,4,5-tetramethylben- zene, ethylbenzene, cumene, o-cymene, m-cymene, p-cymene, o-diisopropylbenzene, m- diisopropylbenzene or p-diisopropylbenzene and acetone, 2-butanone, 2-pentanone, 3-pen- tanone or 2 heptanone. 8. A process according to claim 6 wherein the crystallizing or recrystallizing is from a mixture of benzene, toluene, o-xylene, m-xylene or p-xylene and 1-butanol, 2-butanol or isobutanol; from a mixture of acetone or 2-butanone and isopropanol, 1-butanol or 2-buta- nol; or from a mixture of benzene, toluene, o-xylene, m-xylene or p-xylene and acetone or 2-butanone. 9. A process according to claim 6 wherein the crystallizing or recrystallizing is from a mixture of toluene and 1-butanol; from a mixture of 2-butanone and 1-butanol; or from a mixture of toluene and acetone. 10. The beta, triclinic crystalline form of 2,2',2"-m ' trilo[triethyl-tris-(3,3',5,5'-tetra-tert- butyl-l, -biphenyl-2,2'-diyl) phosphite] obtainable by the process of claim 2 or 6. 11. A composition comprising a) an organic material subjected to oxidative, thermal or light-induced degradation, and b) the beta, triclinic crystalline form of 2,2' ,2"-nitrilo[triethyl-tris-(3,3' ,5,5'-tetra- tert-butyl-l,r-biphenyl-2,2'-diyl) phosphite] as defined in claim 1 and 10. 12. A composition according to claim 11, additionally comprising, apart from components (a) and (b), further additives. 13. A composition according to claim 12, comprising, as further additives, phenolic anti¬ oxidants, light stabilizers or processing stabilizers. 14. A composition according to claim 12, comprising, as the further additive, at least one compound of benzofuran-2-one type. 15. A composition according to claim 11, comprising, as component (a), natural, semi- synthetic or synthetic polymers. 16. A composition according to claim 11, comprising, as component (a), thermoplastic polymers. 17. A composition according to claim 11, comprising, as component (a), a polyolefin. 18. A composition according to claim 11, comprising, as component (a), polyethylene or polypropylene. 19. Use of the beta, triclinic crystalline form of 2,2 , ,2"-nitrilo[triethyl-tris-(3,3',5,5'- tetra-tert-butyl-l, -biphenyl-2,2'-diyl) phosphite], as defined in claim 1 and 10, as stabili¬ zer for organic materials against oxidative, thermal or light-induced degradation. 20. Use according to claim 19, in which the beta, triclinic crystalline form of 2,2',2"-nitri- lo[triethyl-tris-(3,3',5,5'-tetra-tert-butyl-l,r-biphenyl-2,2'-diyl) phosphite], as defined in claim 1 and 10, is used as processing stabilizer (thermal stabilizer) in thermoplastic poly¬ mers. 21. A process for stabilizing an organic material against oxidative, thermal or light-in¬ duced degradation, which comprises incorporating therein or applying thereto the beta, tri¬ clinic crystalline form of 2,2',2"-nitrilo[triethyl-tris-(3,3\5,5'-tetra-tert-butyl-l,r-biphe- nyl-2,2'-diyl) phosphite] as defined in claim 1 and 10.

Inventors: PASTOR STEPHEN D, SHUM SAI P, PASTOR, STEPHEN, D., SHUM, SAI, P.
Applicants: CIBA GEIGY AG, PASTOR STEPHEN D, SHUM SAI P, CIBA-GEIGY AG, PASTOR, STEPHEN, D., SHUM, SAI, P.
Application year: 1993
Main classification: C07F9
IPC codes: C07F9, C08K5, C09K15